Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06586242 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

Study acronym: EASOPCWAAC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Xijing Hospital
179 trials monitored
See 8 trials at risk
Esophageal Cancer
1,049 trials monitored
See 54 trials at risk
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
Trial Details
NCT Number NCT06586242
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Esophageal Cancer
Related terms Esophageal Neoplasms
Enrollment 194 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov